Aligos Therapeutics Inc.

1.40+0.0700+5.26%Vol 130.30K1Y Perf -91.65%
Aug 11th, 2022 16:00 DELAYED
BID1.38 ASK1.45
Open1.40 Previous Close1.33
Pre-Market- After-Market1.43
 - -  0.03 2.14%
Target Price
4.90 
Analyst Rating
Hold 2.60
Potential %
250.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.71
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.18 
Earnings Rating
Market Cap59.93M 
Earnings Date
4th Aug 2022
Alpha-0.10 Standard Deviation0.26
Beta2.78 

Today's Price Range

1.341.41

52W Range

1.0317.97

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-6.67%
1 Month
-0.71%
3 Months
19.66%
6 Months
-45.74%
1 Year
-91.65%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALGS1.400.07005.26
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-2 261.40
-2 196.80
-
-
RevenueValueIndustryS&P 500US Markets
4.48M
0.11
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.65-0.4727.69
Q01 2022-0.66-0.84-27.27
Q04 2021-0.83-0.89-7.23
Q03 2021-0.83-0.786.02
Q02 2021-0.81-0.792.47
Q01 2021-0.90-0.7417.78
Q04 2020-0.90-1.09-21.11
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.65
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume130.30K
Shares Outstanding42.81K
Shares Float37.90M
Trades Count549
Dollar Volume179.17K
Avg. Volume144.81K
Avg. Weekly Volume99.85K
Avg. Monthly Volume82.02K
Avg. Quarterly Volume252.56K

Aligos Therapeutics Inc. (NASDAQ: ALGS) stock closed at 1.4 per share at the end of the most recent trading day (a 5.26% change compared to the prior day closing price) with a volume of 130.30K shares and market capitalization of 59.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 73 people. Aligos Therapeutics Inc. CEO is Lawrence M. Blatt.

The one-year performance of Aligos Therapeutics Inc. stock is -91.65%, while year-to-date (YTD) performance is -88.21%. ALGS stock has a five-year performance of %. Its 52-week range is between 1.03 and 17.97, which gives ALGS stock a 52-week price range ratio of 2.18%

Aligos Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.44, a price-to-sale (PS) ratio of 13.72, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.10%, a ROC of -72.65% and a ROE of -80.82%. The company’s profit margin is -%, its EBITDA margin is -2 196.80%, and its revenue ttm is $4.48 Million , which makes it $0.11 revenue per share.

Of the last four earnings reports from Aligos Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. Aligos Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aligos Therapeutics Inc. is Hold (2.6), with a target price of $4.9, which is +250.00% compared to the current price. The earnings rating for Aligos Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aligos Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aligos Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.03, ATR14 : 0.12, CCI20 : -11.79, Chaikin Money Flow : -0.02, MACD : -0.01, Money Flow Index : 49.37, ROC : 5.26, RSI : 41.90, STOCH (14,3) : 58.82, STOCH RSI : 0.76, UO : 46.68, Williams %R : -41.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aligos Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (20.00 %)
1 (20.00 %)
1 (20.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (80.00 %)
4 (80.00 %)
4 (80.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.60
Hold
2.60
Hold
2.60

Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).

CEO: Lawrence M. Blatt

Telephone: +1 800 466-6059

Address: One Corporate Drive, South San Francisco 94080, CA, US

Number of employees: 73

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

73%27%

Bearish Bullish

70%30%

TipRanks News for ALGS


News

Stocktwits